Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Clinical-stage USA-based biotech Aruvant Sciences today announced the appointment of V "Palani" Palaniappan, as chief technology officer (CTO) effective immediately. 1 June 2020
Biotechnology
Adding to the plethora of indications for the already blockbuster immuno-oncology drug, the US Food and Drug Administration (FDA) on Friday approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy, said Genentech, the US subsidiary of Swiss pharm giant Roche (ROG: SIX). 1 June 2020
Biotechnology
The Japan Ministry of Health, Labor and Welfare (MHLW) has approved Xtandi (enzalutamide), an oral androgen receptor signaling inhibitor, for the treatment of prostate cancer patients with distant metastasis. 29 May 2020
Biotechnology
Danish cancer specialist Genmab has announced positive top-line results from the Phase III ANDROMEDA study of subcutaneous (SC) daratumumab. 29 May 2020
Biotechnology
French drugmaker Ipsen, which has been under interim management since the surprise departure of its chief executive David Meek in December last year, today announced it has appointed David Loew as its new CEO and as board member. The CEO appointment will take effect on July 1, 2020 29 May 2020
Biotechnology
Swiss pharma giant Roche is about to start a Phase III study to evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) plus Gilead Sciences’ antiviral remdesivir. 29 May 2020
Biotechnology
Detailed results from the Phase III ADAURA trial released for the first time showed that Tagrisso (osimertinib) demonstrated a statistically-significant and clinically-meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. 29 May 2020
Biotechnology
US pharma giant Merck & Co has exercised its option to utilize Australian biotech firm Vaxxas’ proprietary High Density Microarray Patch (HD-MAP) platform for a vaccine candidate. Merck also retains an option to license the HD-MAP technology for two additional vaccines. 29 May 2020
Biotechnology
New data in bladder cancer could help make Bavencio (avelumab) more than just an also ran in checkpoint inhibition. 29 May 2020
Biotechnology
Israeli company Protalix BioTherapeutics and family-owned Italian group Chiesi have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for pegunigalsidase alfa to treat Fabry disease. 28 May 2020
Biotechnology
Akcea Therapeutics today announced publication of long-term data from the open-label extension (OLE) of the pivotal NEURO-TTR study of Tegsedi (inotersen) in patients with hereditary amyloidosis transthyretin (hATTR) with polyneuropathy. 28 May 2020
Biotechnology
Japan’s Fujifilm Corp has signed a clinical collaboration agreement with MSD International GmbH, a unit of US pharma giant Merck & Co, for a clinical trial evaluating a combination therapy with the latter’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) and Fujifilm's drug candidate FF-10832, a liposome drug candidate. 28 May 2020
Biotechnology
Shares of USA-based NantKwest gained as much as 20% to $6.53 yesterday after it revealing that its partner, privately-held immunotherapy company ImmunityBio, has been selected to participate in Operation Warp Speed, a new US program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. 28 May 2020
Biotechnology
Azitra, a privately-held dermatology and microbiome specialist, has been awarded Rare Pediatric Disease designation for its candidate ATR-12, for the treatment of Netherton syndrome (NS). 28 May 2020
Biotechnology
The US Food and Drug Administration has approved VESIcare LS (solifenacin succinate) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged two years and older. 28 May 2020
Biotechnology
In a surprise market reaction following the announcement of a lucrative collaboration agreement today, US oncology-focussed biotech Arcus Biosciences saw its shares fall nearly 13% to $29.20 by late morning. 27 May 2020
Biotechnology
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. 27 May 2020
Biotechnology
Californian company AcelRx Pharmaceuticals has announced a revised merger agreement to acquire Tetraphase Pharmaceuticals. 27 May 2020
Biotechnology
New research commissioned by the European Medicines Agency (EMA) will seek to ensure that the region is ready for effective monitoring of potential COVID-19 vaccines, once they are approved and in use. 27 May 2020
Biotechnology
Swiss pharma giant Roche has announced positive top-line results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or wet age-related macular degeneration (nAMD). 27 May 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze